Characteristics | With progression n = 36 | Without progression n = 99 | P-Value |
---|---|---|---|
Serum sodium, mmol/L (mean ± SD) | 132.9 ± 6.2 | 138.1 ± 3.8 | < 0.001 |
Age, yrs. (mean ± SD) | 52.7 ± 11.0 | 50.2 ± 9.5 | 0.207 |
Male | 27 (75%) | 76 (76.8%) | 0.831 |
In-hospital days (M) | 8.3 (4.5–23) | 7.3 (1.8–22) | 0.119 |
Hypertension | 10 (27.8%) | 13 (13.1%) | 0.045 |
Epilepsy | 4 (11.1%) | 14 (14.1%) | 0.864 |
Dyslipidemia | 3 (8.3%) | 12 (12.1%) | 0.757 |
Cerebral infarction | 6 (16.7%) | 7 (7.1%) | 0.180 |
Pulmonary infection | 4 (11.1%) | 3 (3.0%) | 0.152 |
Paralysis of cranial nerves | 7 (19.4%) | 16 (16.2%) | 0.654 |
Nasopharyngeal carcinoma | 33 (91.7%) | 93 (94.0%) | 0.938 |
Glioma | 3 (8.3%) | 5 (5.0%) | 0.762 |
Oral cancer | 0 (0%) | 1 (1.0%) | 1.000 |
Baseline T1-weight gadolinium-contrast area (cm2)(mean ± SD) | 4.5 ± 2.4 | 5.5 ± 3.8 | 0.153 |
BaselineT2-weighted area (cm2) (mean ± SD) | 9.3 ± 5.9 | 10.8 ± 6.4 | 0.200 |